ArticleInvestigational new drugs2023

HLX22, an anti-HER-2 monoclonal antibody, in patients with advanced solid tumors overexpressing human epidermal growth factor receptor 2: an open-label, dose-escalation, phase 1 trial.

Xiaoxue Zhu et al.PubMed ↗Publisher ↗

No numbers read from the abstract.